Early Clinical Success

Prime Medicine's in vivo prime editing program shows acceptable early safety and measurable biological activity in chronic granulomatous disease. This is the most likely constructive path because the IND clearance, RMAT designation, and first-patient dosing indicate the program has already passed several regulatory and translational hurdles.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.